Here are the 10-K annual reports from Context Therapeutics Inc. (CNTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CNTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNTX filings page.
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors, centered on three programs: CTIM-76, CT-95 and CT-202.
CTIM-76, a Claudin 6 x CD3 engager, is in a Phase 1 dose-escalation and expansion trial, with the first patient dosed in January 2025 and Phase 1a interim data expected in June 2026. CT-95, a Mesothelin x CD3 engager acquired for $3.75 million, entered Phase 1 in April 2025, with Phase 1a interim data targeted for September 2026. CT-202, a Nectin-4 x CD3 engager in-licensed from BioAtla for an $11.0 million upfront payment plus milestones and royalties, is preclinical; an application was submitted in March 2026 to the Australian HREC, and first dosing in a Phase 1 trial is planned for the third quarter of 2026.
The company emphasizes significant market opportunities in CLDN6-, MSLN- and Nectin-4–positive relapsed/refractory cancers, retains broad global rights to key patents, and relies on third-party manufacturers and licensors. It highlights substantial ongoing capital needs, dependence on successful clinical development and regulatory approvals, competition from other oncology developers, intellectual property uncertainties and the risk of not maintaining Nasdaq listing requirements.